Skip to content

Clinical Observation Study on Prediction of Long-term Survival and Short-term Death of Stage IV NSCLC with >3 Months Survival by Serum Biomarkers Combined with Clinical Features

Clinical Observation Study on Prediction of Long-term Survival and Short-term Death of Stage IV NSCLC with >3 Months Survival by Serum Biomarkers Combined with Clinical Features

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400090065
Enrollment
Unknown
Registered
2024-09-23
Start date
2023-09-14
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Exposure group:None

Sponsors

Longhua Hospital Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosed pathologically as NSCLC; (2) Stage was defined as IV according to UICC lung cancer 8th edition TNM staging; (3) Expected survival time>3 months; (4) The duration time between enrollment and first diagnosed pathologically as NSCLC is less than 3 months; (5) Age = 18 years old; (6) Traditional Chinese Medicine (TCM) syndromes are: lung spleen qi deficiency, yin deficiency with internal heat, qi yin deficiency, and spleen kidney deficiency; (7) The patinets eligible for the study who can understand the this study, accept long-term follow-up, and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with small cell lung cancers; (2) Stage was defined as I-III according to TNM staging; (3) Dual cancer and multiple cancer patients; (4) Expected survival time < 3 months; (5) It is longer than 3 months from the time of enrollment to the time of initial confirmed pathological diagnosis; (6) Age < 18 years old; (7) Merge acute and chronic diseases that may seriously affect treatment and prognosis, such as myocardial infarction, stroke, severe renal insufficiency, mental illness, pregnant or lactating patients, etc.

Design outcomes

Primary

MeasureTime frame
Overall survival, OS;

Secondary

MeasureTime frame
1, 2-year overal survival rate ;Serum biological markers:CD3, CD4, CD8, CD4/CD8, NK, E2, T, IGF-1, GF, Insuline, IL-2, sIL-2R, TNF-a, IFN-?, VEGF.;QLQ-LC43;ECOG-PS;Traditional Chinese Medicine symptoms;

Countries

China

Contacts

Public ContactGuo Huiru

Longhua Hospital Shanghai University of Traditional Chinese Medicine

ab811712@163.com+86 152 2158 4031

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026